Stoke Therapeutics Chief Medical Officer Ticho Barry sold 5,545 shares in two transactions on 2026-09-01, at prices from $30.51 to $31.06 per share. The transactions leave Barry owning 20,110 shares, giving investors a precise post-sale ownership figure alongside the insider transaction.
Key Highlights
- Ticho Barry sold 5,545 Stoke Therapeutics shares.
- The sales occurred across two separate transactions on 1 September 2026.
- The reported prices ranged from $30.51 to $31.06 per share.
Stoke Therapeutics, Inc. (NASDAQ: STOK) Chief Medical Officer Ticho Barry sold 5,545 shares, leaving him with 20,110 shares after the transactions.
5,545 Shares Sold Across Two Transactions
Barry’s reported activity covered a total of 5,545 Stoke Therapeutics shares. The transactions were carried out under transaction code S and occurred on the same date. The lower end of the price range was $30.51 per share, while the highest reported price was $31.06 per share. Barry was identified in the transaction as Stoke Therapeutics’ chief medical officer. The stated post-transaction balance was 20,110 shares. That figure represents Barry’s ownership after the two sales.
FAQs
Q: How many Stoke Therapeutics shares did Ticho Barry sell?
A: Ticho Barry sold 5,545 Stoke Therapeutics shares across two separate transactions. The Form 4 reports that the sales occurred on 1 September 2026.
Q: What was the impact of Ticho Barry’s Stoke Therapeutics share sale?
A: Following the two transactions, Barry’s reported ownership was 20,110 Stoke Therapeutics shares. The filing identifies him as the company’s chief medical officer.
Q: At what prices did Ticho Barry sell STOK shares?
A: Ticho Barry sold the Stoke Therapeutics shares at prices between $30.51 and $31.06 per share. The sales were completed through two transactions on 1 September 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.